Abstract: A rare earth complex including a rare earth ion and a ligand coordinated with the rare earth ion and having a condensed polycyclic aromatic group.

Abstract: Fluorescent resin particles which comprise a water-soluble fluorescent dye and a polymer made from a monomer mixture.

Abstract: In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are NCDs of metal chelates, including complexes of iron, copper or zinc.

Abstract: A mixed amino acid metal salt complex of the mixed amino acids, lysine and glutamic acid associated with trace metals selected from the group consisting of iron, manganese, copper and zinc to provide highly bioavailable sources of the iron, manganese, copper and zinc and as well to take advantage of the different amino acid transport pathways of lysine and glutamic acid.

Abstract: Provided is a phosphorus molybdenum amine compound, represented by the following general formula (I). where R1 to R6 each independently represent a hydrogen atom or a hydrocarbon group and p represents a number of 1 to 5, provided that all of R1 to R6 are can not all be hydrogen atoms at the same time and the phosphorus molybdenum compound is obtained by reducing a hexavalent molybdenum compound with a reducing agent, and then reacting the resulting with an acidic phosphate after neutralization with a mineral acid.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: Transition metal complexes of selected monoanionic phosphine ligands, which also contain a selected Group 15 or 16 (IUPAC) element and which are coordinated to a Group 3 to 11 (IUPAC) transition metal or a lanthanide metal, are polymerization catalysts for the (co)polymerization of olefins such as ethylene and ?-olefins, and the copolymerization of such olefins with polar group-containing olefins. These and other nickel complexes of neutral and monoanionic bidentate ligands copolymerize ethylene and polar comonomers, especially acrylates, at relatively high ethylene pressures and surprisingly high temperatures, and give good incorporation of the polar comonomers and good polymer productivity. These copolymers are often unique structures, which are described.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: The invention relates to a labeled transition metal complex comprising a transition metal atom, a reactive moiety for allowing a chemical or biological entity to become attached to the transition metal atom, an inert tridentate moiety as a stabilizing bridge, and a marker. The invention also relates to a labeled chemical or biological entity comprising a chemical or biological entity which is attached to said labeled transition metal complex, to the use of said complex for creating a defined shift in the molecular mass of said entity in order to facilitate mass spectrometric analysis of said entity, to methods for rendering chemical or biological entities distinguishable by mass spectrometry as well as to methods for mass spectrometric analysis of the chemical or biological entities.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: The present invention is affinity particles that are characterized by having phosphorylcholine groups represented by the following formula (1) covalently bonded onto the surface of inorganic powder and also by having ligands having specific affinity with a certain target substance covalently bonded or adsorbed onto the surface of inorganic powder. The object of the present invention is to provide an affinity separation method that uses affinity particles utilizing inexpensive inorganic particles and is capable of separating the target substance easily and with high accuracy.

Abstract: Porphyrinic compounds that contain solubilizing groups are described, along with methods of making and using the same and compositions comprising such compounds. Examples of such compounds include compounds of Formula (I) wherein: Z is a porphyrinic macrocyclic, Alk1 and Alk2 are each independently an alkylidene chain; L is a linking group or is absent; R1 is preferably an ionic group or polar group; R2 is an ionic group, polar group, bioconjugatable group, or targeting group: R3 is present or absent and when present is a halo group, bioconjugatable group, or targeting group, n is O or 1 (that is, the CH group is present, or Alk1 and Alk2 are bonded directly to a carbon of the porphyrinic macrocycle Z); or a salt thereof.

Abstract: Provided is a phosphorus molybdenum amine compound, represented by the following general formula (1). where R1 to R6 each independently represent a hydrogen atom or a hydrocarbon group and p represents a number of 1 to 5, provided that all of R1 to R6 are can not all be hydrogen atoms at the same time and the phosphorus molybdenum compound is obtained by reducing a hexavalent molybdenum compound with a reducing agent, and then reacting the resulting with an acidic phosphate after neutralization with a mineral acid.

Abstract: A compound represented by the following general formula (I): wherein R1 and R2 represent an alkyl group or alkenyl group; X1 and X2 represent —O—, or —N(Z)-; Z represents hydrogen atom, or an alkyl group; L represents a divalent bridging group comprising an alkylene group, an alkenylene group, —CO—, —O— and the like wherein number of atoms constituting a chain length of the bridging group is 1 to 10; and Ch represents a partial structure containing 3 or more nitrogen atoms and capable of forming a chelate, and a chelate compound comprising the compound are provided. A vascular lesion can be selectively contrasted by MRI or scintigraphy imaging using a contrast medium comprising liposomes containing said compound or said chelate.

Abstract: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.

Abstract: Bisphosphonate compounds are disclosed, particularly bisphosonate conjugates useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.

Abstract: It is known to polymerize olefins using transition metal complexes and/or compounds. There is an ongoing search for catalysts for olefin polymerization which do not rely on transition metals as the active center. The present invention provides novel aluminum phosphinimine complexes, containing additional heteroatoms which are useful in the polymerization of olefins.

Abstract: An improved detergent for use in hydrocarbon fuels comprising the composition produced by mixing (1) the Mannich reaction product of a polyisobutene-substituted phenol, (preferably, where the polyisobutene from which the substituted phenol is derived contains at least 70% terminal olefinic double bonds of the vinylidene type); an aldehyde; and an amine, preferably, ethylene diamine; and (2) a compound selected from the group consisting of an alkylbenzene sulfonic acid, an alkylnapthalene sulfonic acid, acetylaetone and mixtures thereof. Preferably, the alkylbenzene and alkylnapthalene sulfonic acid is selected to be a (C6 to C18) alkylbenzene sulfonic acid/napthalene sulfonic acid, especially preferred being dodecylbenzene sulfonic acid.

Abstract: The subject of the invention is to provide a new high-performance flame retardant having excellent flame resistant effect and smoke-suppressing effect and generating no hazardous gas, and a new flame retardant resin-composition used it. As a means for solution, a flame retardant comprising ethylenediamine-containing zinc phosphate and other phosphorus-containing compound is formulated in amounts of 10 to 200 parts by weight to 100 parts by weight of resin.

Abstract: Multifunctional molybdenum compounds, which are the reactive product of molybdenum dithiocarbamates and (non-metal containing) dihydrocarbyl dithiophosphoric acids, and the oils that contain them are new compositions which are useful as lubricant additives. They impart to the lubricant formulations to which they are added low friction and excellent friction retention properties.

Abstract: Readily processible cluster compositions of vanadium and phosphorus are precursors to vanadium-phosphorus catalysts including vanadyl pyrophosphate and vanadylbis(metaphosphate).

Abstract: Chiral compounds of the formula I ##STR1## where the variables are as described in the specification.

Abstract: A process for preparing a phosphodiester of the formula: ##STR1## is described that involves (1) reaction of a first alcohol with phosphorous trichloride to form a phosphorodichlorodite, (2) reaction of the phosphorodichlorodite with an amine to form a phosphorodiamidite, (3) reaction with a second alcohol (which may be the same as the first alcohol) to form a phosphoramidite diester, and finally, (4) hydrolysis and oxidation of the phosphoramidite to form the phosphodiester. R and R1 may represent aliphatic, aromatic, heterocyclic, peptidic, peptoid, deoxyribo- or ribonucleotidic or nucleosidic, or organic chelating moieties.

Abstract: New metallocene compounds (II) and their synthetic intermediates (I) used for olefin polymerization catalysts represented by the general formulas (I) and (II) ##STR1## (wherein X can be identical or different and is each independently of one another a halogen atom, M.sup.1 is a group IV transition metal atom, A is a nitrogen or phosphorus atoms, R.sup.1 is an aryl group, R.sup.2 is a saturated hydrocarbon group having 1-10 carbon atoms, whereby each of R.sup.2 can bind one another to constitute a ring containing A and M.sup.1, L.sup.1 and L.sup.2 can be each other identical or different and are a substituted cyclopentadienyl, indenyl, substituted indenyl or substituted fluorenyl groups, B is a hydrocarbon having 1-20 carbon atoms, silylene having 1-20 carbon atoms, oligosilylene or germylene groups, binding to L.sup.1 and L.sup.2, and M.sup.1 can be also coordinated with an ether or an amine at any coordination number.).

Abstract: Heteropolyoxometallates of tungsten, molybdenum and vanadium with a structurally defined micropore volume, a method of production by means of the hydrothermal reaction of the appropriate metal with an associated oxide, a diamine, phosphoric acid and water, and the use of the novel compounds as catalysts.

Abstract: A class of diagnostic and therapeutic compounds derived from phosphinimines that include ligands containing either a single phosphinimine functionality or both a phosphinimine group and a phosphine or arsine group, or an aminato group, or a second phosphinimine moiety. These phosphinimine ligands are complexed to early transition metal radionuclides (e.g. .sup.99m Tc or .sup.186 Re/.sup.188 Re) or late transition metals (e.g., .sup.105 Rh or .sup.109 Pd). The complexes with these metals .sup.186 Re/.sup.188 Re, .sup.99m Tc and .sup.109 Pd exhibit a high in vitro and high in vivo stability. The complexes are formed in high yields and can be neutral or charged. These ligands can also be used to form stable compounds with paramagnetic transition metals (e.g. Fe and Mn) for potential use as MRI contrast agents. Applications for the use of ligands and making the ligands are also disclosed.

Abstract: A new class of vanadium phosphate materials using a mixed valence pentavanadate as the building block has been created using hydrothermal self-assembly techniques. These materials use a framework composed solely of V.sub.5 O.sub.9 (PO.sub.4).sub.4/2 pentamers and apart from the cationic template contain some of the largest voids and cavities yet reported in open framework solids.

Abstract: Novel catalysts of the general formulaMX.sub.a Y.sub.b,in whichM is Pt, Pd, Rh, Ru, Os or Ir,X is a triazene, tetrazene, tetrazadiene or pentazadiene ligand,Y is a ligand selected from Cl, Br, I, NH.sub.3, P(C.sub.2 H.sub.5).sub.3, P(C.sub.6 H.sub.5).sub.3, H, CO, 1,5-cyclooctadiene, pyridine, bipyridine, acetate, acetylacetonate, phenylnitrile, ethylenediamine, acetonitrile, 2,5-norbornadiene, nitrate, nitrite, H.sub.2 O, benzene, diphenylphosphinoethane and 1,3-divinyl-1,1,3,3-tetramethyldisiloxane,a is 1, 2, 3 or 4 andb is 0 or an integer from 1 to 6, are described.The catalysts promote the addition of Si-bonded hydrogen onto an aliphatic multiple bond, in which the catalysts are activated by heating at temperatures of 50.degree. to 250.degree. C., by irradiation with light, by addition of Bronsted acids and/or by addition of acid-forming agents.

Abstract: Novel compounds obtainable by reacting together an imido-reagent such as diphenylphosphonimidotriphenylphosphorane) with a chelate of a transition or lanthanide or actinide metal, such as tris(dibenzoylmethide) europium III, has the property of fluorescing in UV radiation. The invention includes solid polymer bodies containing such compounds, or chelates of transition or lanthanide or actinide metals generally, the bodies having the property of emitting light by virtue of internally generated, e.g. by tritium ionising radiation. The body is preferably of polystyrene formed by polymerising the monomer in the presence of the compound or metal chelate.

Abstract: A vanadium/phosphorus oxide oxidation catalyst suitable for catalytic oxidation of C.sub.4 feed stock in the preparation of maleic anhydride is formed by calcining an intercalation complex of the formula VOHPO.sub.4 .multidot.0.5H.sub.2 O.multidot.({C.sub.n H.sub.2n+1 }--X).sub.z in which n has a value of from 0 to 20, z has a value of from about 1.5 to about 1.9; and X is an oxygen- or nitrogen-containing functional group operable to form hydrogen bonds with the structural P--OH and water groups of the complex.

Abstract: Cyclopentadienyl derivatives are deprotonated by a process whereby the cyclopentadienyl derivatives are reacted with a Grignard reagent in an inert solvent which contains from about 0.5 to 1.5 equivalents per equivalent of cyclopentadienyl derivative of a cyclic ether or an acyclic polyether, so as to form a dianionic salt of said cyclopentadienyl derivative.

Abstract: The deposition of a copper-containing layer on a substrate by decomposing, particularly by a CVD process, a compound corresponding to the formula (I)RO--Cu--L (I)in whichR represents a 1-aryl lower alkyl group, a branched, optionally substituted alkyl group with 3 to 6 carbon atoms, or an aryl group, andL represents (C1 to C6-alkyl)isonitrile, aryl isonitrile, carbon monoxide, dialkylaminodifluorophosphane, organyl difluorophosphane, triaryl phosphane, trialkyl phosphane, trifluorophosphane, or trichlorophosphane,is described, together with previously unknown compounds of formula (I) which may be used in the process.

Abstract: A new class of vanadium phosphate materials has been created using hydrothermanl self-assembly techniques. Of particular interest is that these materials comprise a vanadium phosphate framework structure about an organic template that after removal leave a microporous structure. These materials typically are produced by a reaction in an aqueous solution that includes one or more phosphate sources, one or more vanadium or vanadium oxide sources, an alkali metal or alkali-earth metal sources, and an organic amine or diamine templating agent.

Abstract: Reaction products of an organotin oxide, such as dibutyltin oxide, a diorgano dithiophosphoric acid such as di-(2-ethylhexyl)dithiophosphoric acid and an alkenyl or polyalkenyl succinic anhydride, such as dodecenyl succinic anhydride, are effective multifunctional antioxidant and antiwear additives in lubricants, greases and fuels.

Abstract: A class of new oxide structures containing octahedral molybdenum and tetrahedral phosphorous has been generated using hydrothermal techniques. These materials are produced by the reaction of a molybdenum oxide source with phosphate and any one, or combination of organic cation/alkali-metal cation/organic amine as a templating/mineralizing agent. A reducing agent is necessary to convert the Mo(VI) to a lower valent form and can be either added to the reaction mixture or is provided in the form of one of the reactants.

Abstract: The present invention is directed to tungsten halogen phosphine complex compounds having the formula W(PX.sub.3).sub.6-n L.sub.n wherein X is fluorine or chlorine, L is molecular nitrogen, acetone or other ketones or aldehydes, carbon monoxide, acetonitrile or other nitriles, diphenylethine or other ethines, diethylether or tetrahydrofurane or other open-chained or cyclic ethers, benzene or other aromatics, ethene or 1,5-cyclooctodiene or cycloheptatriene or other mono, di, or, respectively, triolefines, whereby two single-tooth ligands L can be replaced by one .mu..sup.4 -ligand or three single-tooth ligands L can be replaced by one .mu..sup.6 -ligand and n is a whole number from 0 to 5, as well as methods for the manufacture thereof. These substances are easily volatile in a vacuum and can be decomposed at extremely low temperatures and are therefore extremely well suited for CVD depositions in semiconductor technology, particularly, as via hole fillers in VLSI circuits.

Abstract: A coordination compound useful as a hydrogenation catalyst, having the formula: ##STR1## wherein Ph is phenyl; R is hydrogen or C.sub.1 -C.sub.4 alkyl; and X is chloro, bromo or iodo. This compound is particularly useful as a homogeneous hydrogenation catalyst in the production of alpha-6-deoxytetracyclines, particularly the antibiotic doxycycline. The desired alpha-6-deoxy product is produced in high yields and stereospecificities, the process requiring the use of minimal quantities of rhodium metal in the hydrogenation catalyst per mole of the 6-methylenetetracycline hydrogenated.

Abstract: A class of new oxide structures containing octahedral molybdenum and tetrahedral phosphorous has been generated using hydothermal techniques. These materials are produced by the reaction of a molybdenum oxide source with phosphate and any one, or combination of organic cation/alkali-metal cation/organic amine as a templating/mineralizing agent. A reducing agent is necessary to convert the Mo(VI) to a lower valent form and can be either added to the reaction mixture or is provided in the form of one the reactants.

Abstract: The invention relates to a zirconium phosphate in particles having sizes comprised within the range of from 1 to 100 .mu.m, a lamellar structure with interlayer distance, in the anhydrous state, comprised within the range of from 7.9 to 8.2 .ANG. and a surface area comprised within the range of from 9 to 20 m.sup.2 /g.The method consists in altering the lamellar structure of a zirconium phosphate with layer structure of alpha type by intercalating into it an organic substance containing a proton-acceptor group and water and by a treatment with ultrasounds, in regenerating the hydrogen form of said zirconium phosphate by an acid and in washing the same with diluted acids and/or water.

Abstract: The diacylesters, particularly bis(pyridyl-3-carboxilate) of glycerylphosphorylcholine, both optically active L(alpha) or racemic D,L(alpha) and their complexes having general formula: ##STR1## wherein: Y represents ##STR2## M represents Ca, Mg, Al, Zn X represents a halogen, particularly chlorine, n=2,3 ed m=0,1 are anti-dislipemic and cerebroactive agents.Their preparation takes place through acylation with an anhydride of a complex of glycerylphosphorylcholine with calcium or zinc chloride.

Abstract: A compound having the formula: ##STR1## wherein each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is a hydrogen atom, an alkyl group having from 1 to 22 carbon atoms, an unsubstituted or substituted aromatic group having from 6 to 20 carbon atoms and an aralkyl group having from 7 to 20 carbon atoms, and A.sup..crclbar. is a molybdic acid anion, a tungstic acid anion or a heteropolyacid anion containing molybdenum or tungsten atoms.

Abstract: The diacylesters, particularly bis(pyridyl-3-carboxilate) of glycerylphosphorylcholine, both optically active L(alpha) or racemic D, L(alpha) and their complexes having general formula: ##STR1## wherein: Y represents ##STR2## M represents Ca, Mg, Al, Zn X represents a halogen, particularly chlorine, n=2,3 ed m=0,1 are anti-dislipemic and cerebroactive agents.Their preparation takes place through acylation with an anhydride of a complex of glycerylphosphorylcholine with calcium or zinc chloride.

Abstract: Novel platinum(II) complexes of 1,2-diaminocyclohexane, 1-aminomethylcyclooctylamine and 1,2-diamino-2,4-dimethylpentane are provided. Such complexes are of use in inhibiting the growth of certain mammalian tumors.

Abstract: Tin compounds, a process for the preparation thereof, a process for the preparation of a medicine using such a tin compound for the treatment of malignant tumors in mice as well as the shaped medicine thus obtained.This invention relates to novel tin compounds, a pharmaceutical composition using the novel compounds and methods for treating cancer using the pharmaceutical composition.